Table 4.
Comparison between EOSD and AOSD Cases Complicated with MAS.
| EOSD with MAS n=5 |
AOSD with MAS n=48 [Ref. 46] |
|||
|---|---|---|---|---|
| Epidemiology | ||||
| Mean age, years old | 76.9±8.4 | 40.2±16.0 | ||
| Females, n (%) | 5 (100) | 35 (72.9) | ||
| Treatment for MAS | ||||
| Glucocorticoids, n (%) | 4 (80) | 43 (90) | ||
| Cyclosporine, n (%) | 2 (40) | 14 (29) | ||
| Anti- IL-6, n (%) | 1 (20) | - | ||
| IVIG, n (%) | - | 19 (40) | ||
| Methotrexate, n (%) | - | 11 (23) | ||
| Cyclosphosphamide, n (%) | - | 6 (13) | ||
| Anakinra, n (%) | - | 1 (2) | ||
| Anti-TNF, n (%) | - | 1 (2) | ||
| Immediate outcome | ||||
| Alive, n (%) | 5 (100) | 42 (88) | ||
| Deceased, n (%) | - | 6 (12) | ||
| Follow up time, months | 14.2±6.5 | 17.5±32.3 |
EOSD: elderly-onset Still’s disease, AOSD: adult-onset Still’s disease, MAS: macrophage activation syndrome, IL-6: interleukin-6, IVIG: intravenous immunoglobulin, TNF: tumor necrosis factor